Summary
This prediction ended on 16.06.23 with a price of €21.94. With a performance of -5.47%, the BUY prediction by DirectorDealer finished with a loss. DirectorDealer has a follow-up prediction for Evotec SE, but this time predicts that Evotec SE is a Sell. DirectorDealer has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Evotec SE | -30.593% | -30.593% | -44.574% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% |
Comments by DirectorDealer for this prediction
In the thread Evotec AG diskutieren
Director's Dealing / Insider Kauf von Lanthaler, Dr. Werner (Vorstand)
- Handelstag: 14.06.2022
- Volumen: 226854 €
- Meldende_r: Lanthaler, Dr. Werner
In the thread Trading Evotec AG
Die von DirectorDealer gewählte maximale Laufzeit wurde überschritten